Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-012-1433-2DOI Listing

Publication Analysis

Top Keywords

thrombosis severe
4
severe asthenia
4
asthenia priority
4
priority manifestations
4
manifestations paroxysmal
4
paroxysmal nocturnal
4
nocturnal haemoglobinuria
4
thrombosis
1
asthenia
1
priority
1

Similar Publications

Endovascular therapy versus anticoagulation alone for subacute iliofemoral deep vein thrombosis.

J Vasc Interv Radiol

December 2024

Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China; Vascular Center of Shanghai JiaoTong University, Shanghai, China. Electronic address:

Purpose: This study evaluated whether endovascular therapy (ET) improved early symptom relief and decreased the incidence of moderate-to-severe post-thrombotic syndrome (PTS) compared to anticoagulation alone in patients with subacute (15-28 days) iliofemoral deep vein thrombosis (DVT).

Materials And Methods: Consecutive patients with subacute iliofemoral DVT from January 2020 to June 2022 were identified. A total of 86 patients were categorized to treatment with ET alongside anticoagulation (endovascular group, n = 49) or anticoagulation alone (anticoagulation group, n = 37).

View Article and Find Full Text PDF

Thymidine phosphorylase participates in platelet activation and promotes inflammation in rheumatoid arthritis.

Toxicol Appl Pharmacol

December 2024

Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Electronic address:

The elevated risk of cardiovascular disease (CVD) associated with inflammatory rheumatic diseases has long been recognized. Patients with established rheumatoid arthritis (RA) have a higher mortality rate compared to the general population due to abnormal platelet activation. Thymidine phosphorylase (TYMP) plays a crucial role in platelet activation and thrombosis, following bridging the link between RA and CVD.

View Article and Find Full Text PDF

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

EBioMedicine

December 2024

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. Electronic address:

Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.

View Article and Find Full Text PDF

Background: Trauma and pregnancy are both risk factors for venous thromboembolism (VTE). We hypothesized that pregnant blunt trauma patients would have a higher incidence of VTE complications compared with matched nonpregnant females.

Methods: We conducted a retrospective cohort study using National Trauma Data Bank data from 2017 to 2022.

View Article and Find Full Text PDF

Noncardiogenic pulmonary edema after cardiac surgery is a rare but severe complication. The etiology remains poorly understood; however, the issue may arise from multiple sources. Possible causes include a significant inflammatory response or an autoimmune process.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!